Explore scalable strategies for iPSC-derived islet differentiation using GMP-grade activin A and KGF to advance diabetes ...
The approval of this accelerated pathway not only demonstrates the FDA’s full recognition of the quality, safety, and efficacy of the Phase 1 clinical data of hNPC01 in China, but also will ...
Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...
Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma Patient-specific human immune system-bearing mouse ...
A group of researchers in Japan says it has confirmed a certain level of efficacy in using iPS cell-derived immune cells for ...
PHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in ...
Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies ...
As of Thursday, January 08, Century Therapeutics, Inc.’s IPSC share price has surged by 30.65%, which has investors questioning if this is right time to sell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results